Author

H. Bläker

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell signaling & trafficking· 1 Research Focus:cell type annotation· 1 Research Focus:chromatin & epigenetic regulation· 1 Research Focus:development & morphogenesis· 1 Research Focus:differential expression· 1 Approach:experimental assay· 1

Frequent Co-Authors

A. Ahadova· 2 shared M. Kloor· 2 shared M. von Knebel Doeberitz· 2 shared S. Haupt· 2 shared V. Heuveline· 2 shared A. B. Riemer· 1 shared A. Ballhausen· 1 shared A. Benner· 1 shared

Activity by Year

2019-2020 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

A. Ahadova

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

A computational model for investigating the evolution of colonic crypts during Lynch syndrome carcinogenesis

S. Haupt, N. Gleim, A. Ahadova, H. Bläker, M. von Knebel Doeberitz, M. Kloor, V. Heuveline

This paper develops a computational model to simulate colonic crypt evolution in Lynch syndrome, showing the importance of stem cell dynamics and MMR deficiency in CRC development.

bioRxiv · Dec 29, 2020Cancer Biology

The shared neoantigen landscape of MSI cancers reflects immunoediting during tumor evolution

A. Ballhausen, M. J. Przybilla, M. Jendrusch, S. Haupt, E. Pfaffendorf, M. Draxlbauer, F. Seidler, S. Krausert, A. Ahadova, M. S. Kalteis, D. Heid, J. Gebert, M. Bonsack, S. Schott, H. Bläker, , M. Kloor

The study identifies shared immunogenic neoantigens in MSI cancers and finds a negative correlation between indel mutation frequency and neoantigen immunogenicity, suggesting immunoediting during tumor evolution.

bioRxiv · Jul 16, 2019Cancer Biology